ICLE 2022 | CRISPR-Cas9 genome editing technology in the development of T cell therapies
Alessio Nahmad
• 31 Mar 2022
Alessio Nahmad, PhD, Tel Aviv University, Tel Aviv, Israel, explains how genome editing technology can be utilized in the development of T cell-based therapies. Selective gene ablation using CRISPR-Cas9 technology can help enhance efficiency, reduce toxicity and reduce cellular exhaustion in T cell products such as chimeric antigen receptor (CAR)-T cell and T cell receptor (TCR) therapies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
